- Overall GLP-1 prescribing rates (GLP-1 RA prescriptions per total prescriptions) in June 2025 increased slightly relative to March 2025 (+7.7%).
- Tirzepatide is now the most prescribed anti-diabetic (ADM) and anti-obesity (AOM) medication (sold as Mounjaro and Zepbound, respectively).
- For patients with first-time anti-obesity medication prescriptions in March 2025, only 49.2% had evidence of a prescription fill within 60 days, compared to 72.9% of patients receiving anti-diabetic medication prescriptions; this indicates there may be ongoing access issues related to cost or insurance.
Limited recent data exist on prescribing patterns and patient characteristics for GLP-1 RA medications, whether used as anti-diabetic medication (ADM) for patients with type 2 diabetes (T2D) and/or used as an anti-obesity medication (AOM) for patients with overweight or obesity. Interest in these medications has recently accelerated, largely for their weight-loss effects, although access to and use of GLP-1 RA medications may be impacted by high cost, limited insurance coverage for patients without T2D and medication shortages.
To offer insight into the latest trends about these medications, Truveta Research has created the GLP-1 RA monitoring report, which will be updated periodically with fresh, timely data. Truveta Data provides the most representative, complete, and timely patient journey data, including full patient medical records, notes, and images, for more than 120 million patients across the US. Truveta Data is also linked with closed claims for more than 200 million patients. Because Truveta Data is updated daily, we can show the latest trends in these medications.
This blog provides a snapshot of the key findings in the most recent report; including prescribing and dispensing medication (indicates whether the patient picked up the medication) trends. For the full analysis – inclusive of demographics, comorbidities, and social drivers of health data for the population, methodology, additional findings, limitations, and citations – you can view the complete report on MedRxiv or directly within Truveta Studio.
Key findings: Prescribing trends
Using a subset of Truveta Data, Truveta Research identified people who were prescribed a GLP-1 RA between January 01, 2018 and June 30, 2025. We describe prescribing volumes and patient characteristics over time, by medication, and by FDA-labeled use (e.g., ADM, AOM, or unknown).
Overall prescribing trends
The study found that 2,196,747 patients were prescribed a GLP-1 RA between January 2018 and June 2025, with 10,622,359 total prescriptions during this period.
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in June 2025 increased slightly relative to March 2025 (+7.7%).
Month-over-month ADM prescribing increased in April and then remained relatively stable through June 2025. ADM prescribing in June 2025 is about the same as March 2025 (+2.1%).
Among ADMs, tirzepatide is now the most prescribed ADM medication.
AOM prescribing increased each month between March and June 2025, which an overall increase of +22.4%. AOM tirzepatide and semaglutide both increased in rates between March and June 2025; however, tirzepatide increased by 32.0% to reach an overall prescription rate of 1.3%, while AOM semaglutide increased by 8.1% to reach an overall prescription rate of 0.7%.
Trends in first-time prescribing
First-time prescribing rates (first-time GLP-1 RA prescriptions per total prescriptions) in June 2025 are slightly decreased compared to March 2025 (-4.8%). First-time prescribing of ADMs decreased in June 2025, relative to March 2025 (- 15.1%). First-time prescribing of AOMs increased in June 2025, relative to March 2025 (+8.5%).
First-time prescribing of both ADM (-22.8%) and AOM (-5.3%) semaglutide decreased throughout the quarter. First-time prescribing of ADM tirzepatide slightly decreased (-1.4%), while first-time prescribing of AOM tirzepatide (16.4%) increased throughout the quarter.
Dispense trends
Dispense refers to prescription fills, indicating that the patient picked up the medication from their pharmacy and provides the closest proxy for use.
During the full time period, 71.1% of GLP-1 RA prescriptions had a dispense within 60 days of their prescription (e.g., were initiated within 60 days).
For patients first prescribed an ADM in March 2025, 72.9% filled a GLP-1 RA within 60 days. Initiation rates for ADM GLP-1 RA are about the same in March 2025, relative to December 2024 (+4.2%).
For patients first prescribed an AOM in March 2025, 49.2% filled a GLP-1 RA within 60 days. Initiation rates for AOM GLP-1 RA are about the same in March 2025, relative to December 2024 (-1.3%).
As a proxy for Medicare insurance, we segmented initiation rate by populations aged 65 and older versus those aged 18-64.
Discussion
With the popularity of GLP-1 RA medications and challenges in access and insurance coverage, we will continue to monitor these prescribing and dispensing trends over time.
The GLP-1 RA monitoring report describes more detailed information about the overall population of patients being prescribed these medications (including demographics and comorbidities), and the proportion and characteristics of patients who filled a GLP-1 RA prescription over time using dispenses. Methodologies, limitations, and citations are also available in the full report. You can also view the full study – including codes, definitions, and more – directly in Truveta Studio.
These are preliminary research findings and not peer reviewed. All data are preliminary and may change as additional data are obtained. These findings are consistent with data accessed July 11, 2025. Data presented in this analysis represent raw counts and/or rates, and post-stratification methods have not been conducted.